Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders 239: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 1
What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?
Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few more days, he's running continuous E. coli processes for up to 40 days; something most believed impossible.
Here's why this conversation is worth your notebook and a second listen:
- Why the commodity CDMO model struggles with innovation and how enGenes Biotech's model aligns business incentives with process improvement (02:37)
- Juergen Mairhofer's early experiences blending molecular biology and bioprocess engineering, and how a "DIY" mentality led to entrepreneurship (04:42)
- Strategy behind developing a proprietary E. coli strain that decouples protein production from cell growth (10:01)
- The benefits of continuous manufacturing: running up to 40-day E. coli processes, and how this compares to mammalian (CHO) systems (13:57)
- Economic and operational advantages: reducing facility footprint, lowering CAPEX/OPEX, and the necessity for innovation in global competition (19:25)
- How enGenes Biotech integrates upstream and downstream operations for fully end-to-end continuous production (17:50)
- Specific technical challenges: managing genetic drift, sterility, equipment, and process modeling in continuous systems (21:10)
Smart insight: Technology excellence is the entry ticket, but it won't sell itself. The companies that will lead the next decade of bioprocessing are those willing to align their business model with process innovation, not just capacity utilization.
If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:
- Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
- Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
- Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
- Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
- Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
- Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos
Connect with Juergen Mairhofer:
LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b
enGenes Biotech GmbH website: www.engenes.cc
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.